Aytu Biopharma, Inc. AYTU
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -5.09% | -2,177.79% | -366.29% | -109.14% | 14.40% |
| Total Depreciation and Amortization | -26.91% | -21.90% | -22.35% | -22.04% | -20.04% |
| Total Amortization of Deferred Charges | 4.63% | -48.61% | -68.29% | -76.89% | -81.91% |
| Total Other Non-Cash Items | -36.92% | 839.84% | 920.37% | 435.36% | -12.44% |
| Change in Net Operating Assets | 197.28% | 142.13% | -263.73% | -3.57% | 10.85% |
| Cash from Operations | 269.39% | 130.35% | -188.41% | 42.33% | -39.55% |
| Capital Expenditure | 87.28% | 93.70% | 78.13% | 80.22% | 30.70% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -100.00% | -70.79% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -1,116.95% | -1,300.00% | -4,047.37% | -- |
| Cash from Investing | 98.87% | -817.26% | -794.18% | -2,397.66% | -678.12% |
| Total Debt Issued | -100.00% | -89.56% | -55.21% | -20.67% | -38.37% |
| Total Debt Repaid | -160.96% | 89.11% | 88.44% | 88.26% | 88.19% |
| Issuance of Common Stock | -- | 338.92% | 338.92% | 328.04% | 328.04% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 49.71% | -24.85% | -118.39% | -783.59% | -113.63% |
| Cash from Financing | -151.13% | 181.35% | 5,408.76% | 606.17% | 1,323.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -142.43% | 638.25% | 1,007.83% | 8,595.83% | 467.44% |